You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2025

Bulk Pharmaceutical API Sources for MEFENAMIC ACID


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for MEFENAMIC ACID

Vendor Vendor Homepage Vendor Sku API Url
ChemBlock ⤷  Get Started Free A1077/0050549 ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free M4267_SIGMA ⤷  Get Started Free
NovoSeek ⤷  Get Started Free 4044 ⤷  Get Started Free
MP Biomedicals ⤷  Get Started Free 193920 ⤷  Get Started Free
ISpharm ⤷  Get Started Free I14-3644 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: MEFENAMIC ACID

Last updated: August 4, 2025


Introduction

Mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID), is widely used for managing mild to moderate pain, including menstrual pain and dental discomfort. As with many APIs, the sourcing of bulk mefenamic acid involves a complex global supply chain comprising chemical manufacturers, contract manufacturing organizations (CMOs), and distributors. Ensuring a reliable, compliant, and cost-effective API supply chain is crucial for pharmaceutical companies aiming to maintain product quality, regulatory compliance, and market competitiveness. This article provides a comprehensive overview of the key sources for bulk mefenamic acid, highlighting manufacturing regions, supplier profiles, and quality considerations.


Manufacturing Regions and Key Suppliers

1. China

China remains a dominant player in the global API manufacturing landscape, particularly for NSAIDs like mefenamic acid. Chinese API producers have developed extensive technical expertise and manufacturing facilities adhering to international standards, such as Good Manufacturing Practices (GMP). Many Chinese manufacturers supply bulk mefenamic acid to global pharmaceutical companies, often offering competitive pricing due to lower production costs.

Notable Chinese API Manufacturers include:

  • Hubei Hekang Bio-Tech Co., Ltd.
    Specializes in pain management APIs, ISO-certified, with GMP-compliant facilities.

  • Shandong Xinhua Pharmaceutical Co., Ltd.
    Offers a range of NSAIDs, including mefenamic acid, with manufacturing licenses recognized globally.

  • Zhejiang Hisun Pharmaceutical Co., Ltd.
    A large pharmaceutical group with extensive API production capabilities for NSAIDs.

Considerations: Due diligence regarding quality standards, regulatory compliance, and prior audit histories is essential before engaging Chinese suppliers.

2. India

India has established itself as a significant API manufacturing hub, particularly renowned for complex chemical synthesis and low-cost production. Indian manufacturers producing mefenamic acid often supply both domestic and international markets.

Leading Indian API producers include:

  • BASF India Ltd. (through contract manufacturing partners)
    Known for high-quality APIs with strict adherence to global standards.

  • Aarti Industries Ltd.
    Offers a broad portfolio of APIs, including NSAIDs, with GMP certification.

  • Granules India Ltd.
    Serves as a contract manufacturer and bulk API supplier with extensive experience in NSAIDs.

Quality Assurance: Indian manufacturers often possess stringent GMP certifications (like USFDA, EDQM), and many have multiple audit approvals from global regulators.

3. Europe

European manufacturers emphasize high-quality standards and regulatory compliance, often supplying APIs for markets with strict regulatory environments like the US and EU.

Key European API Suppliers include:

  • Evonik Industries AG (Germany)
    Provides high-purity APIs with certifications aligning with international standards.

  • Euroapi (formerly part of Sanofi) (France)
    Specializes in manufacturing complex APIs, including NSAIDs, with a focus on quality and regulatory compliance.

Note: Europe generally functions as a high-end niche supplier source, often characterized by premium pricing but excellent quality assurance.

4. Other Notable Regions

  • South Korea and Japan
    Known for innovative chemical processes and strict quality standards, though less prevalent for inexpensive APIs like mefenamic acid.

  • United States
    Limited API production for mefenamic acid but primarily relies on imports, with some domestic contract manufacturers capable of producing high-standard APIs.


Contract Manufacturing and Sourcing Strategies

Pharmaceutical companies increasingly favor contract manufacturing organizations (CMOs) for sourcing mefenamic acid due to advantages in capacity, scale, and regulatory expertise.

Advantages of CMO sourcing include:

  • Flexibility in batch sizes
  • Reduced capital expenditure for in-house manufacturing
  • Access to specialty manufacturing technologies
  • Regulatory support and documentation expertise

Major CMOs with experience in NSAID synthesis include:

  • Hikal Ltd. (India)
  • PCAS (France)
  • Suzhou North Biological Technology Co., Ltd. (China)

Strategic considerations: Companies should ensure CMOs maintain rigorous quality management systems, transparent supply chain documentation, and robust compliance with global GMP standards.


Quality and Regulatory Considerations

When sourcing mefenamic acid, quality assurance is paramount. Suppliers must provide Certificates of Analysis (CoA), Batch Production Records, and compliance documentation aligned with ICH guidelines. Regulatory agencies, such as the U.S. FDA, EMA, and CDSCO in India, enforce rigorous standards on API manufacturing, including Good Manufacturing Practice (GMP).

Essential Quality Aspects:

  • Purity (>99%)
  • Particulate matter control
  • Residual solvents
  • Impurity profiling
  • Stability and shelf-life data

Before procurement, thorough supplier qualification, audits, and validation ensure the API's regulatory acceptance in target markets.


Emerging Trends in API Sourcing

  • Supply Chain Diversification: To mitigate risk, companies are diversifying sources across regions. This includes engaging multiple suppliers from different countries.

  • Regulatory Alignment: Suppliers are aligning manufacturing processes with evolving standards (e.g., ICHQ7, PIC/S), streamlining global approval processes.

  • Sustainability and Compliance: Growing emphasis on environmentally sustainable manufacturing practices and transparency.


Challenges in API Sourcing

  • Trade and Tariffs: Geopolitical tensions and tariffs may impact cost and availability.
  • Regulatory Barriers: Variability in approval status across countries can complicate sourcing.
  • Quality Variability: Ensuring consistent API quality remains a persistent challenge, underscoring the importance of rigorous supplier qualification.
  • Intellectual Property (IP) considerations: Reverse engineering of APIs can pose IP risks; due diligence is necessary when engaging new suppliers.

Conclusion

The global API supply chain for mefenamic acid is characterized by key manufacturing hubs in China, India, and Europe, each offering distinct advantages in cost, quality, and regulatory compliance. Strategic sourcing for mefenamic acid involves a combination of thorough supplier qualification, adherence to quality standards, and diversification to mitigate supply risks. As companies navigate evolving regulatory landscapes and geopolitical shifts, selecting reliable, compliant suppliers is crucial for uninterrupted market access and product integrity.


Key Takeaways

  • Chinese and Indian manufacturers dominate the mefenamic acid API landscape due to cost advantages and extensive production capacity.
  • European suppliers focus on high-quality, regulatory-compliant APIs suitable for strict markets.
  • Contract manufacturing organizations provide flexibility and expertise, especially for scale-up or regulatory approval processes.
  • Rigorous quality and regulatory compliance remain vital in selecting API sources, with audits and documentation providing assurance.
  • Supply diversification and transparency are essential strategies to mitigate risks associated with geopolitical, trade, or quality issues.

FAQs

Q1: What are the primary regions sourcing bulk mefenamic acid globally?
A1: The main regions are China, India, and Europe, each offering distinct advantages in pricing, quality, and regulatory compliance.

Q2: How do I ensure supplier quality for mefenamic acid?
A2: Conduct comprehensive supplier qualification, including audits, review of GMP certification, batch documentation, and stability profiles.

Q3: Are there any regulatory considerations when sourcing from Chinese suppliers?
A3: Yes, suppliers should have GMP certification recognized by relevant authorities (FDA, EMA, etc.), and continuous validation is recommended to ensure compliance.

Q4: Can I source mefenamic acid from contract manufacturers?
A4: Yes, partnering with experienced CMOs can streamline production; ensure they meet your quality and regulatory standards.

Q5: What are the risks associated with sourcing API from emerging markets?
A5: Risks include variability in quality, regulatory differences, supply chain disruptions, and intellectual property concerns. Proper due diligence mitigates these issues.


References

[1] U.S. Food & Drug Administration (FDA). Guidance for Industry: API Manufacturing Standards. 2021.
[2] European Medicines Agency (EMA). Good Manufacturing Practice: Guidelines. 2022.
[3] Pharamceutical Commerce Journal. Trends in API Sourcing. 2022.
[4] International Council for Harmonisation (ICH). Quality Guidelines (Q7). 2016.
[5] Global Chemical & Pharma Reports. API Industry Overview. 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.